DRI Capital, headquartered in New York, NY, is a pioneer in pharmaceutical royalty monetization, specializing in building a diversified portfolio of interests in medicines that effectively treat unmet medical needs. With over 20 years of experience, DRI Capital strategically acquires patent-protected cash flow streams from the sales of essential drugs across various therapeutic areas.
As a best-in-class partner for investors and innovators, DRI Capital offers tailored, creative, and flexible structures to meet the needs of its deal partners. The company actively sources royalty streams on medically necessary products with long-term patent protection and high growth potential, providing investors with a risk-mitigated portfolio of therapeutic assets aiming to generate attractive returns and significant growth.
Generated from the website